broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K38332599-001-01-3 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.065984 | 0.493219 | 0.71383 | 0.675203 | 0.478047 | 0.636924 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000974 |
BRD-K38527262-300-01-0 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.127536 | 6.033161 | 0.761913 | 0.868623 | 2.135015 | 2.241806 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000974 |
BRD-K38852836-001-02-1 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.108448 | 2.264598 | 0.908671 | 0.550973 | 0.018878 | 0.02103 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000974 |
BRD-K39974922-001-04-3 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.968461 | -0.35777 | -0.004888 | 0.97666 | 2.748407 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000974 |
BRD-K41859756-001-06-8 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.174138 | 1.305372 | 0.855777 | 0.496219 | 0.006693 | 0.00929 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000974 |
BRD-K42495768-001-01-7 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 1.223883 | 0.171462 | -0.240428 | 1 | 0.73369 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000974 |
BRD-K42805893-001-04-9 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.112787 | 5.699222 | 0.654152 | 0.910743 | 3.769487 | 3.942412 | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000974 |
BRD-K42828737-001-03-3 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.012936 | 5.286545 | 0.436744 | 0.932481 | 5.178409 | 5.204149 | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000974 |
BRD-K42898655-001-01-8 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.560964 | 2.484316 | 0.593915 | 0.693813 | 0.000718 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000974 |
BRD-K43389675-001-02-1 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.088516 | 3.26819 | 0.820725 | 0.699234 | 0.406699 | 0.431682 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000974 |
BRD-K44227013-001-06-4 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.091747 | 3.453035 | 0.683478 | 0.774207 | 0.895897 | 0.950068 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000974 |
BRD-K44408410-001-17-6 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.086257 | 5.042817 | 0.554066 | 0.943426 | 5.537508 | 5.749356 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000974 |
BRD-K44827188-001-06-0 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.706443 | 0.161164 | -0.001901 | 0.95222 | 3,081.515683 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000974 |
BRD-K46386702-001-02-1 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.529376 | 0.158117 | 0.115602 | 0.826964 | 2.834804 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000974 |
BRD-K49328571-001-15-0 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.005453 | 0.122745 | 0.31614 | 0.343604 | 0.000302 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000974 |
BRD-K49350383-001-14-5 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 1.79018 | 2.807016 | 0.373975 | 1 | 4.034262 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000974 |
BRD-K50010139-001-01-5 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.318385 | 11.076194 | 0.288353 | 0.945823 | 4.623943 | 5.066742 | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000974 |
BRD-K50168500-001-07-9 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.065742 | 4.774347 | 0.448105 | 0.857514 | 2.276601 | 2.344822 | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000974 |
BRD-K51313569-001-07-8 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 1.074676 | 0.086848 | -0.00407 | 1 | 0.010896 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000974 |
BRD-K51791723-003-01-7 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.100585 | 4.281302 | 0.571485 | 0.78627 | 0.996468 | 1.050141 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000974 |
BRD-K51967704-001-03-6 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.204924 | 1.328203 | 0.76546 | 0.676324 | 0.193096 | 0.28722 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000974 |
BRD-K52313696-001-12-3 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.944077 | -7.082976 | -0.016125 | 0.944077 | 41.206609 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000974 |
BRD-K53414658-001-08-2 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | -0.391907 | 2.54696 | 0.481747 | 0.970279 | 11.534604 | 9.190115 | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000974 |
BRD-K53972329-001-07-0 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.753337 | 1.562397 | -0.020426 | 0.965805 | 2.831128 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000974 |
BRD-K54256913-001-08-7 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.274933 | 3.586531 | 0.607975 | 0.906 | 2.850573 | 3.561169 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000974 |
BRD-K54955827-001-02-2 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.572496 | -0.315715 | -0.310213 | 0.826265 | 0.018818 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000974 |
BRD-K54997624-001-06-0 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.718796 | 0.556305 | 0.049133 | 0.86704 | 0.105632 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000974 |
BRD-K55187425-236-05-2 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.230106 | 12.866548 | 0.516055 | 0.618278 | 0.081343 | 0.085338 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000974 |
BRD-K56343971-001-14-8 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.497323 | 4.004983 | 0.463835 | 0.854645 | 0.604339 | 2.23057 | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000974 |
BRD-K56981171-001-02-8 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.269876 | 2.801481 | 0.629943 | 0.866811 | 1.707083 | 2.251888 | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000974 |
BRD-K57169635-001-04-5 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.081717 | 1.083762 | 0.589338 | 0.722136 | 0.551313 | 0.649993 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000974 |
BRD-K58435339-001-03-0 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.237837 | 1.196116 | 0.884799 | 0.601429 | 0.062425 | 0.107096 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000974 |
BRD-K58529924-001-01-5 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | -0.181977 | 4.577275 | 0.561446 | 0.967418 | 8.748415 | 8.174821 | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000974 |
BRD-K58550667-001-08-7 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.139605 | 6.141653 | 0.766687 | 0.711141 | 0.024032 | 0.025348 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000974 |
BRD-K59317601-001-05-5 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.088136 | 0.591066 | 0.571465 | 0.633639 | 0.22896 | 0.317863 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000974 |
BRD-K60866521-001-07-1 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.86637 | 0.075668 | -0.055931 | 0.930663 | 0.028463 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000974 |
BRD-K60997853-001-02-3 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.143299 | 1.860141 | 0.601443 | 0.75208 | 0.604754 | 0.725139 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000974 |
BRD-K61192372-001-08-9 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.949964 | -0.478332 | 0.029075 | 0.963627 | 1.311031 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000974 |
BRD-K62008436-001-23-9 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.153893 | 6.082419 | 0.719782 | 0.617431 | 0.007764 | 0.008248 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000974 |
BRD-K62196610-001-01-6 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.375323 | 3.941087 | 0.538571 | 0.807711 | 0.504236 | 0.71727 | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000974 |
BRD-K62200014-003-10-5 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.941625 | -0.064911 | -0.058996 | 0.972703 | 0.010417 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000974 |
BRD-K62391742-001-09-7 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 1.027581 | -0.126213 | -0.006317 | 1 | 0.165215 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000974 |
BRD-K62627508-001-01-5 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.273142 | 0.506907 | 0.694772 | 0.635911 | 0.07729 | 0.367451 | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000974 |
BRD-K63504947-001-14-7 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 1.218544 | 2.282221 | 0.134248 | 1 | 0.19398 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000974 |
BRD-K64052750-001-22-5 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.673871 | 0.603234 | 0.020037 | 0.875185 | 0.280741 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000974 |
BRD-K64881305-001-03-7 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.173524 | 5.816746 | 0.823769 | 0.403653 | 0.009097 | 0.009789 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000974 |
BRD-K66175015-001-12-4 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.049881 | 1.450138 | 0.673427 | 0.746219 | 0.760844 | 0.818028 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000974 |
BRD-K67844266-003-01-9 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.202754 | 1.482318 | 0.790817 | 0.663402 | 0.166404 | 0.236336 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000974 |
BRD-K69001009-001-02-8 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.092915 | 0.588583 | 0.515183 | 0.721738 | 0.681373 | 0.966225 | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000974 |
BRD-K69694239-001-02-2 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.207707 | 4.068733 | 0.840218 | 0.64114 | 0.123314 | 0.140707 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000974 |
BRD-K69776681-001-03-8 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.077463 | 0.553861 | 0.46724 | 0.469985 | 0.033978 | 0.046045 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000974 |
BRD-K70301465-001-05-9 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.588109 | 0.591345 | 0.308501 | 0.823022 | 0.168226 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000974 |
BRD-K70401845-001-15-7 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.097803 | 0.980697 | 0.229018 | 0.878253 | 3.755523 | 4.688808 | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000974 |
BRD-K73838513-003-05-5 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.684733 | 4.622198 | 0.382056 | 0.901405 | 0.480755 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000974 |
BRD-K74514084-003-09-2 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.876394 | 0.020078 | -0.026408 | 0.93727 | 0.0175 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000974 |
BRD-K75009076-001-02-1 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | -0.102279 | 3.813278 | 0.545237 | 0.942913 | 6.307356 | 6.006907 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000974 |
BRD-K76210423-001-01-6 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 1.126567 | -0.378416 | -0.035644 | 1 | 0.000983 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000974 |
BRD-K76239644-001-02-6 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | -0.215317 | 0.539849 | 0.654535 | 0.714173 | 1.868127 | 0.962299 | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000974 |
BRD-K76674262-001-03-3 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.101299 | 2.050446 | 0.866348 | 0.565472 | 0.091662 | 0.102364 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000974 |
BRD-K77625799-001-07-7 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.142767 | 2.265059 | 0.685053 | 0.844946 | 1.742992 | 2.021945 | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000974 |
BRD-K78431006-001-15-1 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.127284 | 0.370337 | 0.40381 | 0.727381 | 1.10038 | 2.432606 | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000974 |
BRD-K79254416-001-21-8 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.527553 | 0.435972 | 0.275087 | 0.777885 | 0.113023 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000974 |
BRD-K81016934-001-02-0 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.913636 | 0.040625 | -0.001164 | 0.96281 | 77.317574 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000974 |
BRD-K81418486-001-44-2 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.698286 | 0.354399 | -0.006374 | 0.840987 | 0.053564 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000974 |
BRD-K81473043-001-19-5 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 1.131534 | 0.268688 | -0.013114 | 1 | 0.000003 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000974 |
BRD-K82746043-001-19-3 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.291235 | 0.69635 | 0.443425 | 0.640212 | 0.072153 | 0.252911 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000974 |
BRD-K82818427-001-04-8 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 1.685368 | 2.051271 | 0.053388 | 1 | 4.579527 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000974 |
BRD-K83029223-001-01-3 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.091627 | 1.5594 | 0.879089 | 0.425746 | 0.00135 | 0.001537 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000974 |
BRD-K83988098-001-02-0 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.590649 | 0.20042 | -0.045062 | 0.693748 | 0.000004 | null | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000974 |
BRD-K85402309-043-01-9 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.647087 | 0.487377 | 0.066778 | 0.80676 | 0.023292 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000974 |
BRD-K85606544-001-09-1 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.435691 | 3.590805 | 0.337805 | 0.81657 | 0.426591 | 0.755212 | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000974 |
BRD-K87737963-001-06-0 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.500667 | 0.052921 | 0.035142 | 0.783583 | 12.692322 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000974 |
BRD-K87782578-001-01-4 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.153568 | 1.45828 | 0.213097 | 0.799555 | 1.029281 | 1.323755 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000974 |
BRD-K87909389-003-03-4 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.089534 | 2.297085 | 0.804273 | 0.583657 | 0.118222 | 0.128826 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000974 |
BRD-K88510285-001-17-8 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.133493 | 7.004454 | 0.730361 | 0.611071 | 0.032124 | 0.033581 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000974 |
BRD-K89014967-001-04-3 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.414762 | 0.269038 | 0.328688 | 0.746207 | 0.241395 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000974 |
BRD-K92441787-001-04-1 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 1.165578 | -0.610759 | -0.078078 | 1 | 0.207342 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000974 |
BRD-K92723993-001-17-4 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 1.021686 | -0.506369 | -0.001699 | 1 | 10.307304 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000974 |
BRD-K95142244-001-01-5 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.511207 | 3.925133 | 0.216367 | 0.922806 | 2.161029 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000974 |
BRD-K96123349-236-02-8 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.907839 | 1.899193 | 0.09925 | 0.95268 | 0.068545 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000974 |
BRD-K98572433-001-02-9 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.106391 | 1.517153 | 0.729251 | 0.757447 | 0.726634 | 0.850752 | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000974 |
BRD-K99113996-001-02-0 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.404639 | 7.829731 | 0.460615 | 0.89203 | 1.720536 | 2.126064 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000974 |
BRD-K99616396-001-05-1 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 0.832237 | 0.520462 | -0.004059 | 0.878623 | 0.005437 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000974 |
BRD-K99749624-001-07-0 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 1.267509 | 3.787992 | 0.202972 | 1 | 0.042867 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000974 |
BRD-M97302542-001-04-4 | ACH-000974 | SNGM_ENDOMETRIUM | MTS010 | 1 | 1.242493 | -1.205232 | 0.283435 | 1 | 0.181055 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000974 |
BRD-A25234499-001-19-1 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 0.840754 | 7.488853 | 0.148922 | 0.941909 | 0.290089 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000976 |
BRD-A70858459-001-01-7 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 0.963288 | -0.021095 | -0.040305 | 0.982342 | 0.002114 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000976 |
BRD-A74914197-001-02-9 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 1.661601 | 0.455687 | -0.295092 | 1 | 0.518148 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000976 |
BRD-K02113016-001-19-6 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 0.995673 | 0.290044 | -0.166076 | 0.99727 | 0.009223 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000976 |
BRD-K02130563-001-11-4 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 0.540178 | 0.399099 | -0.067284 | 0.722017 | 0.010714 | null | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000976 |
BRD-K03390685-001-01-7 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 0.151971 | 2.245987 | 0.813209 | 0.569421 | 0.07245 | 0.085132 | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000976 |
BRD-K03406345-001-21-1 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 1.019287 | -0.019272 | -0.075534 | 1 | 102,622,621.815773 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000976 |
BRD-K03449891-001-08-6 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 0.899574 | 5.557451 | 0.28405 | 0.908021 | 0.001223 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000976 |
BRD-K03765900-001-01-9 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 0.485578 | 1.602011 | 0.536137 | 0.906384 | 1.776231 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000976 |
BRD-K05804044-001-18-5 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | -0.394838 | 0.487364 | 0.583606 | 0.78562 | 8.401269 | 2.545007 | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000976 |
BRD-K06814349-304-02-7 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 1.035676 | -0.127353 | -0.114552 | 1 | 0.033567 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000976 |
BRD-K08109215-001-06-4 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 1.134188 | 0.417542 | 0.109448 | 1 | 0.227359 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000976 |
BRD-K08542803-001-02-3 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 0.027583 | 0.591397 | 0.843119 | 0.625389 | 0.275243 | 0.302963 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000976 |
BRD-K08547377-001-04-4 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 0.900167 | 1.544623 | 0.028694 | 0.927624 | 0.008708 | null | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000976 |
BRD-K08703257-001-13-9 | ACH-000976 | HUCCT1_BILIARY_TRACT | MTS010 | 1 | 1.167141 | -0.164105 | -0.011429 | 1 | 0.021138 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000976 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.